title: IL-33 isoforms: their future as vaccine adjuvants?
abstract: The identification and characterization of cytokine isoforms is likely to provide critical important new insight into immunobiology. Cytokine isoforms can provide additional diversity to their complex biological effects that participate in control and protection against different foreign pathogens. Recently, IL-33 has been identified as a proinflammatory cytokine having several different biologically active isoform products. Originally associated with Th2 immunity, new evidence now supports the role of two IL-33 isoforms to facilitate the generation of protective Th1 and CD8 T cell immunity against specific pathogens. Therefore, a better understanding of the IL-33 isoforms will inform us on how to utilize them to facilitate their development as tools as vaccine adjuvants for immune therapy.
authors: Department of Pathology, University of Pennsylvania, 505A Stellar-Chance Laboratories, 422 Curie Blvd, Philadelphia, PA 19104, USA.
authors: Daniel O
authors: DO
authors: Villarreal
authors: David B
authors: DB
authors: Weiner
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D035843:Biomedical Research / Q000639:trends; D006801:Humans; D000067596:Interleukin-33; D007378:Interleukins / Q000008:administration & dosage* / Q000235:genetics*; D020033:Protein Isoforms / Q000008:administration & dosage / Q000235:genetics; D014612:Vaccines / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; C506536:IL33 protein, human; D000067596:Interleukin-33; D007378:Interleukins; D020033:Protein Isoforms; D014612:Vaccines
keywords: CD8 T cell; DNA vaccine; IL 33; adjuvant; cancer vaccine; cytokine; immunotherapies; isoform
references: Front Immunol. 2013 May 06;4:104
references: 23653627
references: Med Oncol. 2014 Sep;31(9):143
references: 25106529
references: Semin Immunol. 2013 Dec 15;25(6):449-57
references: 24230466
references: Genes Immun. 2009 Mar;10(2):132-40
references: 19092841
references: J Immunol. 2012 Jul 1;189(1):403-10
references: 22634619
references: Int Immunol. 2008 Jun;20(6):791-800
references: 18448455
references: J Invest Dermatol. 2012 Nov;132(11):2661-4
references: 22785132
references: J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S53-72
references: 19932918
references: Immunol Res. 2012 Apr;52(1-2):89-99
references: 22392053
references: Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1673-8
references: 22307629
references: Cancer Res. 2014 Mar 15;74(6):1789-800
references: 24448242
references: Nature. 2014 Sep 25;513(7519):564-8
references: 25043027
references: Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10486-91
references: 22689946
references: J Biol Chem. 2011 Jun 3;286(22):20078-86
references: 21454686
references: Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11489-94
references: 20534524
references: Cytokine. 2011 Nov;56(2):272-81
references: 21843952
references: Science. 2012 Feb 24;335(6071):984-9
references: 22323740
references: J Clin Invest. 2003 Aug;112(4):474-80
references: 12925685
references: Curr Opin Immunol. 2014 Jun;28:102-6
references: 24762410
references: Oncoimmunology. 2014 Jun 03;3:e29030
references: 25083328
references: Eur J Immunol. 2011 Nov;41(11):3351-60
references: 21887788
references: Eur J Immunol. 2009 Apr;39(4):1046-55
references: 19266498
references: J Immunol. 2009 Nov 15;183(10):6469-77
references: 19841166